In addition, DLEU2 promotes glycolysis in EC [12] and TC [19]; EMT in GC [17], CRC [27], and ccRCC [13]; and epigenetic changes in DLEU2 expression in PC [38] and AML [8], indicating the value of multi-target combination therapy with DLEU2. The gene discussed is DLEU2; the disease is colorectal carcinoma.